image credit: Pixabay

Siga seeks FDA approval for intravenous smallpox therapy

May 11, 2021


Siga Technologies has filed for FDA approval of an intravenous formulation of its smallpox treatment Tpoxx. The new formulation is designed to enable the treatment of patients who cannot swallow the already-approved capsules.

The FDA approved an oral formulation of Tpoxx in 2018 for the treatment of human smallpox disease in adults and children weighing 13 kg or more. Siga has contracts to supply oral Tpoxx to Canada and the U.S. but also acknowledges the limitations of the formulation in some populations, leading it to work on an intravenous version of the antiviral.

Read More on FiercePharma